INITIAL PUBLIC OFFER OF 12,850.02 EQUITY SHARES OF FACE VALUE OF ₹ 10 EACH ("EQUITY SHARES") OF YATHARTH HOSPITAL & TRAUMA CARE SERVICES LIMITED ("THE COMPANY") ON "AS A PRICE AT A PRICE OF ₹ 12 PER EQUITY SHARE INCLUDING A SHARE PREMIUM OF ₹ 2 PER EQUITY SHARE ("OFFER PRICE") AGGREGATING TO ₹ 1,54,20,00,000 (THE "OFFER") comprising a Fresh Issue of 16,333,333 Equity Shares aggregating to ₹ 1,99,99,99,990 (The "Fresh Issue") by our Company (the "FRESH ISSUE") and an Offer for Sale of 6,100,000 Equity Shares aggregating to ₹ 1,75,20,00,000 by the Selling Shareholders (the "SOLD BY", comprising 36,25,000 Equity Shares by Neeraj Tyagi, 25,000 Equity Shares by Swati Tyagi and 1,122,900 Equity Shares by Vimla Tyagi) (The "OFFER FOR SALE") aggregating to ₹ 7,32,90,00,000 by Neeraj Tyagi and 5,46,00,000 by Swati Tyagi (The "OFFERED SHARES") .

The Average cost of acquisition of Equity Shares held by our Promoters, members of Promoter Group and the Selling Shareholders as at November 3, 2021, our Company was converted into a public limited company and consequently, the Inception of our Company, the Certificate of Incorporation dated November 18, 2021 was issued by the RoC. For details of change in name and registered office of our Company, please refer to "Registered Office" on page 126 of the Prospectus.

Note: The industry average has been considered from the industry peer set provided in section titled "Basis for Offer Price" on page 126 of the Prospectus.

Details of price to earnings ratio, market capitalization to revenue from operations and enterprise value to EBITDA of certain of our listed peers are given in the table below:

<table>
<thead>
<tr>
<th>Name</th>
<th>Price to Earnings Ratio</th>
<th>Market Capitalization to Revenue from Operations</th>
<th>Enterprise Value to EBITDA</th>
</tr>
</thead>
<tbody>
<tr>
<td>Promoters</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Kapil Kumar</td>
<td>946.90</td>
<td>16.62%</td>
<td>32.96</td>
</tr>
<tr>
<td>Neeraj Tyagi</td>
<td>1,122.90</td>
<td>14.74%</td>
<td>32.96</td>
</tr>
<tr>
<td>Swati Tyagi</td>
<td>782.60</td>
<td>12.75%</td>
<td>32.96</td>
</tr>
<tr>
<td>Vimla Tyagi</td>
<td>948.90</td>
<td>16.62%</td>
<td>32.96</td>
</tr>
<tr>
<td>Total</td>
<td>949.90</td>
<td>16.62%</td>
<td>32.96</td>
</tr>
</tbody>
</table>

Price Restrictions:

1. The Offer Price, market capitalization to revenue from operations and enterprise value to EBITDA of each of our listed peers is shown in the table above.

2. The offer price has been fixed at ₹ 12 per Equity Share.

3. Details of price to earnings ratio, market capitalization to revenue from operations and enterprise value to EBITDA of all our listed peers are given in the table above.

4. The Offer Price has been determined on the basis of a price to earnings ratio of 13.88, a market capitalization to revenue multiple of 15.05 and enterprise value to EBITDA of 32.96.

RISKS TO INVESTORS

1. The Offer Price, market capitalization to revenue from operations and enterprise value to EBITDA of the Offer Price for our Company may not be indicative of the market price of the Company on an listing or thereafter.

2. Details of our price to earnings ratio, market capitalization to revenue from operations and enterprise value to EBITDA of all our listed peers is given in the table above.

3. Price restrictions in the Government in certain instances such as during COVID-19 could adversely affect our business, results of operations and financial condition.

4. Our Company will not receive the entire proceeds from the Offer. Some of our Shareholders are selling their shares in the Offer and will receive proceeds from the Offer.

5. We are highly dependent on doctors, nurses and other healthcare professionals and our business and financial performance will be significantly affected if we are unable to attract, retain or replace such professionals. Attrition rate in Doctors was 65.40%, 22.50% and 40.95% in Fiscal 2021, Fiscal 2022 and Fiscal 2023 respectively.

6. Our operations are concentrated in the Delhi NCR region. With three out of four hospitals in Delhi NCR. We are also significantly dependent on a majority of our revenues. Any impacts the revenue losses from hospitals in our top segment, may affect the overall results of our operations.

7. If we are unable to increase our hospital occupancy rates, we may not be able to generate adequate returns on our capital expenditures, and our operating efficiencies and financial condition could be adversely affected.

8. The average cost of acquisition of Equity Shares held by our Promoters, members of Promoter Group and the Selling Shareholders as at the date of the Prospectus is as given in the table above.

9. The average cost of acquisition of Equity Shares held by our Promoters, members of Promoter Group and the Selling Shareholders as at the date of the Prospectus is as given in the table above.

10. The average cost of acquisition of Equity Shares held by our Promoters, members of Promoter Group and the Selling Shareholders as at November 3, 2021, our Company was converted into a public limited company and consequently, the Inception of our Company, the Certificate of Incorporation dated November 18, 2021 was issued by the RoC. For details of change in name and registered office of our Company, please refer to "Registered Office" on page 126 of the Prospectus.

11. The Three Book Running Lead Managers associated with the Offer have handled 27 public issues in the past three Financial Years, out of which 11 issues closed below the price on the listing date.

12. The basis of Allotment was finalized in consultation with the Designated Stock Exchange, being BSE on August 2, 2023.

13. The Book Building Process ended on Friday, July 28, 2023. The Offer was made through the Book Building Process, in terms of Rule 19(2)(b) of the Securities Contracts (Regulation) Rules, 1957, as amended ("SCRR").

14. The basis of Allotment was finalized in consultation with the Designated Stock Exchange, being BSE on August 2, 2023.

15. The basis of Allotment was finalized in consultation with the Designated Stock Exchange, being BSE on August 2, 2023.

16. The Book Running Lead Managers associated with the Offer were in the ratio of 3:1 to the Offer Price.

17. The Three Book Running Lead Managers associated with the Offer have handled 27 public issues in the past three Financial Years, out of which 11 issues closed below the price on the listing date.

18. The Number of Equity Shares and Percentage of pre-Offer stakeholding of Promoters as at the date of the Prospectus are given in the table above.
The category-wise details of the Basis of Allotment are as under (Sample):

<table>
<thead>
<tr>
<th>NO.</th>
<th>CATEGORY</th>
<th>NO. OF APPLICATIONS RECEIVED</th>
<th>PER APPLICANT</th>
<th>% OF TOTAL</th>
<th>NO. OF EQUITY SHARES ALLOCATED</th>
<th>RATIO</th>
<th>NO. OF EQUITY SHARES ALLOCATED</th>
</tr>
</thead>
<tbody>
<tr>
<td>1</td>
<td>0.20 million and up to 1.00 million</td>
<td>2,000</td>
<td>1,000</td>
<td>2.00</td>
<td>2,000</td>
<td>1:1</td>
<td>2,000</td>
</tr>
<tr>
<td>2</td>
<td>0.10 million and up to 0.20 million</td>
<td>1,000</td>
<td>500</td>
<td>1.00</td>
<td>1,000</td>
<td>1:1</td>
<td>1,000</td>
</tr>
<tr>
<td>3</td>
<td>0.05 million and up to 0.10 million</td>
<td>500</td>
<td>250</td>
<td>0.50</td>
<td>500</td>
<td>1:1</td>
<td>500</td>
</tr>
<tr>
<td>4</td>
<td>0.025 million and up to 0.05 million</td>
<td>250</td>
<td>125</td>
<td>0.25</td>
<td>250</td>
<td>1:1</td>
<td>250</td>
</tr>
<tr>
<td>5</td>
<td>0.01 million and up to 0.025 million</td>
<td>125</td>
<td>63</td>
<td>0.13</td>
<td>125</td>
<td>1:1</td>
<td>125</td>
</tr>
</tbody>
</table>

The IPO Committee of our Company in its meeting held on August 02, 2023 has taken on record the Basis of Allotment of Equity Shares approved by the Designated Stock Exchange, being BSE and allotted the Equity Shares to various successful Bidders. The Allotment Advice-cum-Unlocking intimation has been dispatched to the email of all successful Bidders as registered with www.intensivefiscal.com. Further, the instructions to the Designated Intermediary have been dispatched to unblock the funds, transfer to Public Offer Account on the basis of the shares allotted.

The IPO Committee has received listing and trading approval from NSE and BSE and the trading will commence on August 07, 2023. All capitalised terms used and not specifically defined herein shall have the same meaning as ascribed to them in the Prospectus.

INVESTORS PLEASE NOTE

The details of the Allotment made will be hosted on the website of the Register to the Offer, Link intime India Private Limited at www.linkintime.co.in

All future correspondence in this regard may kindly be addressed to the Register to the Offer quoting full name of the First/Second Bidder, Bid Application Form Number, Bidder ID, Client ID, PAN, date of submission of Bid cum Application Form, address of the Bidder, number of Equity Shares applied for, the name and address of the designated intermediary where the Bid cum Application Form was submitted by the Bidder and a copy of the Acknowledgment Slip received from the designated intermediary at the address given below:

**Note:**

- The allotment made will be hosted on the website of the Register to the Offer, Link Intime India Private Limited at www.linkintime.co.in
- All future correspondence in this regard may kindly be addressed to the Register to the Offer quoting full name of the First/Second Bidder, Bid Application Form Number, Bidder ID, Client ID, PAN, date of submission of Bid cum Application Form, address of the Bidder, number of Equity Shares applied for, the name and address of the designated intermediary where the Bid cum Application Form was submitted by the Bidder and a copy of the Acknowledgment Slip received from the designated intermediary.

**LETTER OF SUBSCRIPTION**

The level of subscription should not be taken to be indicative of either the market price of the Equity Shares on listing or the business prospects of Yatharth Hospital & Trauma Care Services Limited.

**Yatharth Hospital & Trauma Care Services Limited**

C-101, 247 Park, 1st Floor, L.B.S. Marg, Vikhroli (West), Mumbai 400 083, Maharashtra, India
Tel: +91 810 811 4949, E-mail: yatharth.ipo@linkintime.co.in
Investor grievance e-mail: yatharth.ipo@linkintime.co.in, Website: www.linkintime.co.in

**Contact person:** Shari Gopal Krishnan; Contact person: Sd/-

**For Yatharth Hospital & Trauma Care Services Limited**

On behalf of the Board of Directors

**Chairman:** Rash Mishra

Date: August 05, 2023

Company Secretary and Compliance Officer

**Adfactors**